SYRE — Spyre Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636282 ·
Last close
$85.69
Market Cap
$7.56B
52W High
$110.18
52W Low
$15.49
ADV30
1,229,693
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -81,639,000 | -36,200,000 | 1,173,003,000 | 162,007,000 | 71,862,000 |
| Mar 2026 | 0 | — | -75,641,000 | -69,005,000 | 763,953,000 | 97,185,000 | 93,142,000 |
| Dec 2025 | 0 | — | -57,172,000 | -62,530,000 | 777,781,000 | 85,721,000 | 62,545,000 |
| Sep 2025 | 0 | — | -56,888,000 | -11,183,000 | 504,604,000 | 64,897,000 | 49,504,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-208,944,000
Investing CF
$-463,735,000
Financing CF
$753,027,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.05
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,232,840,000
Inventory
—
Receivables
—
ST Investments
$983,339,000
EBIT TTM
$-271,340,000
Pretax Income TTM
$-178,918,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -219,562,000 | — | 777,781,000 | 62,545,000 | 715,236,000 | -169,252,000 |
| Dec 2024 | 0 | -208,566,000 | -208,018,000 | 608,484,000 | 90,680,000 | 517,804,000 | -157,410,000 |
| Dec 2023 | 886,000 | -128,564,000 | -338,790,000 | 341,859,000 | 157,843,000 | 184,016,000 | -99,910,000 |
| Dec 2022 | 2,329,000 | -84,781,000 | -83,815,000 | 71,144,000 | 20,839,000 | 50,305,000 | -80,144,000 |
| Dec 2021 | — | — | -65,801,000 | — | — | — | — |
TTM Snapshot
Revenues TTM
$174,000
NetIncome TTM
$-172,142,000
OpCashFlow TTM
$0
Assets (Latest)
$777,781,000
Forward EPS
$-3.52
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $90.00 · spot: $85.79 · call volume: 33 · put volume: 36
Expected Move to 2026-10-16:
±$9.80
(11.42%) —
implied range
$75.99 –
$95.59
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IONS | IONIS PHARMACEUTICALS INC | $7.40B | $44.50 | — |
| PRAX | Praxis Precision Medicines, Inc. | $7.84B | $280.78 | — |
| ABVX | Abivax S.A. | $7.95B | $91.06 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.89B | $19.77 | — |
| ALKS | Alkermes plc. | $6.85B | $40.85 | — |
News headlines (Yahoo Finance, 1h cache)
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
2026-09-17 07:04 · Yahoo
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
2026-09-10 23:59 · Yahoo
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
2026-09-08 12:00 · Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
2026-09-04 20:01 · Yahoo
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-03 20:05 · Yahoo
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
2026-09-03 15:30 · Yahoo
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked
2026-09-01 02:59 · Yahoo
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating
2026-08-26 20:04 · Yahoo
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
2026-08-26 12:25 · Yahoo
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
2026-08-25 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.